even if they do have enough mild patients to see a stat significant effect in that group, i'm not sure it will be approvable based on a subset. What do you think?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.